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recPrP Recombinant prion protein 
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sCJD Sporadic Creutzfeldt-Jakob disease 
TNF-α Tumor-necrosis factor α  
TNT Tunneling nanotube 
TPrP Toxic prion protein 
TSE Transmissible spongiform encephalopathy 
UV Ultra-violet 
vCJD Variant Creutzfeldt-Jakob disease 
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CHAPTER I 
LITERATURE REVIEW 
 
1.1 Prion 
1.1.1 From disease to prion protein 
Scrapie, a prion disease in sheep, has been recognized over 250 years 
throughout the world.  In 1914, scrapie was regarded as a muscle disease caused by a 
parasite infection [1].  After two decades, the transmission of scrapie was 
demonstrated, which led to the concept that etiological agent of scrapie was a virus [2, 
3].  Because the disease progression is slow, it was named as the unconventional 
slow virus [4].  However, based on the findings of two studies, a virus or a viroid 
was ruled out being the pathogen of scrapie at that time.  First, the infectivity of 
scrapie is not affected by exposure to the 245 nm ultra-violet (UV) irradiation that 
induces the polynucleotide damage [5].  Second, chemical or enzymatic 
modification of nucleic acids does not cause inactivation of scrapie agent [6].  
Nevertheless, scrapie is inactivated by pretreatment with protein denature chemical 
agents or proteases, which is strong evidence that the scrapie agent contains protein.  
Also, in the phenyl-Sepharose column, the scrapie agent is difficult to be eluted 
without a detergent, which indicates it is a hydrophobic particle [7].  In 1982, a new 
term “prion” was proposed for scrapie agent by Dr. Stanley B. Prusiner, which was 
derived from the term “proteinaceous infectious” [6].   
After pretreatment with proteinase K, the brain tissue from the scrapie-infected 
hamsters shows a band at 27-30 kD, designated as PrP27-30, in a western blot assay, 
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but this protein is not found in health hamsters [8].  Through the purification of 
PrP27-30, the N-terminal amino acid sequence of PrP27-30 was determined, giving a key 
for creating the cDNA clone and identifying its mRNA [9].  With cDNA probes, the 
PrP27-30 specific mRNA was found in the brain tissue from both the healthy and 
scrapie-infected hamsters [10].  In a southern blot study, PrP27-30-related DNA 
sequences were detected in normal mice, hamsters and humans [11].  The findings 
suggested that PrP27-30 is a component of the normal protein in brain tissue, and it is 
encoded from a chromosomal gene.  By using the same technique, PrP27-30-related 
polynucleotide was not found in the purified scrapie agent, further confirming that the 
scrapie pathogen was not a virus or a viroid [11].  A complete cDNA clone and open 
reading frames were identified in hamsters in 1986, and Prnp gene was located on a 
single coding exon [12, 13].  This finding disproved the hypothesis that the 
protease-resistant prion protein, designated as PrPSC, is created by alternative splicing 
from Prnp gene, but the mechanism for producing PrPSC remained elusive.  In a 
western blot study, cellular prion protein (PrPC) and PrPSC were distinguished by 
limited proteolysis [14].  In addition, the size of PrPC is the same as PrPSC, 33-35 kD, 
and both are only found in the cellular membrane fraction, which indicates a 
membrane protein.  
 
1.1.2 The structure of prion protein 
Through Fourier-transform infrared (FTIR) spectroscopy and circular dichroism 
(CD) spectrum, the secondary structure of PrPC and PrPSC were identified [15].  The 
content of PrPC was 42% α-helix and 3% β-sheet, but PrPSC had 30 % α-helix and 
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43% β-sheet.  These results indicated that the major difference between PrPC and 
PrPSC is the protein secondary structure, β-sheet, which may capacitate the resistance 
to proteases.  In an electron microscopy study, the rod-shape aggregates were formed 
by polymerization of PrP27-30, which contained 54% β-sheet, but it was not detected in 
purified PrPC or PrPSC solution.  The above findings suggested that β-sheet 
participates in the formation of aggregates.  Due to the insolubility of PrPSC, there is 
no high-resolution structure of PrPSC, which impedes the understanding of the process 
of forming aggregates.  Through simulation analysis of low-resolution projection 
map of PrPSC and dimer structure of recombinant prion protein (recPrP), the β-sheet 
on PrPSC was found to be responsible for intermolecular interaction and promotes the 
formation of PrPSC trimers [16-19].  In addition, based on the dimer structure of 
recPrP, it was hypothesized that the formation of PrPSC is due to the conformational 
change from α-helix to β-sheet [16].   
The structure of PrPC was further studied by X-ray crystallography and nuclear 
magnetic resonance (NMR) in recPrP [16, 20, 21].  The C-terminal of PrP is a 
globular structure consisting of three α-helices (residues 143-152, 171-191 and 
199-221) and two antiparallel β-sheets (residues 127-129 and 166-168) (Figure 1).  
The N-terminal of PrP is unstructured, but the histidine-containing octarepeat (residue 
51-90) binds with Cu2+, which causes “folding” in this region [22].  In addition, a 
highly hydrophobic region (residue 112-130) makes PrP capable of forming an 
abnormal transmembrane structure, designated CtmPrP, in endoplasmic reticulum (ER), 
and over-accumulation of CtmPrP causes cell death [23].  There are three 
posttranslational modifications on PrP, including disulfide bond (between residues 
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179 & 214), N-linked glycosylation (residue 180 & 196) and 
glycosylphosphatidylinositol (GPI) anchor (residue 230-254).  In vitro studies 
showed that expression of unglycosylated PrPC or blockade of PrPC glycosylation 
facilitates the infection of prion disease [24, 25].  It is likely that the N-linked 
oligosaccharides on PrPC efficiently prevent the direct intermolecular interaction, 
which decreases the chance of conformational changes.  In Creutzfeldt-Jakob disease 
(CJD) studies, a different type of CJD showed a distinct glycosylated pattern due to 
the different polysaccharides modification, which can be used to distinguish strains of 
CJD [26, 27].  An in vitro study showed that excessive recPrP on artificial plasma 
membrane induced the conformational change, which increased the content of β-sheet 
[28].  Amyloid plaques were found in the brain of scrapie-infected transgenic mice, 
expressing anchorless PrP, but with minimal clinical manifestations [29].  These 
results indicated that the GPI anchor is crucial for replication of PrPSC and 
development of prion disease.  Also, there is a possibility that accumulation of 
excessive PrPC on the plasma membrane induces conformational changes and creates 
abnormal PrP.   
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Figure 1. The amino acid sequence and structure of PrPC.  Residues correspond 
to the mouse sequence and the structure are based on the NMR analysis.  ++++, 
polybasic region; Cu2+, copper binding domain; SP, signal peptide; HD, hydrophobic 
domain; GPI, glycosylphosphatidylinositol.  Reprinted from Trends in 
Neurosciences, 35(2), Biasini et al., Prion protein at the crossroads of physiology and 
disease, 92-103, Copyright (2012), with permission from Elsevier. 
 
1.1.3 Replication and cytotoxicity of PrPSC 
Here, two models illustrate the replication of PrPSC.  In vivo studies indicated 
that the conformational change of PrPC is through the formation of PrPC/PrPSC 
complex, and the process involve multiple intermolecular interactions [30-32].  
However, because it is difficult to purify the PrPC/PrPSC complex, the mechanism of 
conformational conversion is still unclear.  Based on this observation, the 
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“template-directed refolding” model is proposed.  The intermolecular interactions 
overcome the energy barrier of conversion of PrPC into PrPSC, and eventually PrPC 
turns itself into PrPSC (Figure 2A).  Another hypothesis is called “seeded nucleation” 
which suggests that PrPC and PrPSC are in a reversible equilibrium [33, 34].  In the 
normal state, the majority of PrP is in the PrPC conformation, but in the diseased state, 
most of PrP shifts toward the PrPSC conformation (Figure 2B).  Subsequently, PrPSC 
aggregates into a highly ordered oligomer that serves as a seed for a faster 
propagation, and eventually forms amyloid.  The fragmentation of amyloid creates 
more seeds for recruiting more PrPSC.  In addition, the replication of PrPSC is 
affected by the amount and amino acid sequence of PrPC.  There are 16 amino acid 
differences between the mouse PrP and the hamster PrP, and it could affect 
intermolecular interactions, causing a slower conformational conversion.  The 
inoculation time for the development of prion disease in transgenic mice with 
expression of hamster PrP is prolonged, which supports the species barrier in prion 
disease [35, 36].  Ablation of PrPC in mice decreases the propagation of PrPSC and 
the disease progression, which further confirms that PrPC is the source for replication 
of PrPSC [37, 38].  
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Figure 2. Models for the replication of PrPSC.  (A) The “template-directed 
refolding” model.  The interactions between PrPC and PrPSC overcome the energy 
barrier of conformational conversion, and PrPC turns itself into PrPSC.  Monomer 
PrPSC is able to continually convert other PrPC, and finally PrPSC aggregates into 
amyloid.  (B) The “seeded nucleation” model.  PrPC and PrPSC are in a reversible 
equilibrium, and the formation of a highly ordered seed is slow.  Once the seed is 
formed, it recruits more PrPSC to aggregate into amyloid.  The fragmentation of 
amyloid increases the amount of seeds that recruit more PrPSC to form amyloid. 
 
The question that needs to be addressed is how PrPSC causes cytotoxicity and 
induces cell death.  Purified PrPSC from scrapie-infected mice causes the increase of 
intracellular Ca2+ concentration in N2A neuroblastoma cells, but it is prevented by 
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pretreatment with thapsigargin that depletes the ER Ca2+ stores [39].  The increase of 
intracellular Ca2+ concentration induces the calpain-caspase 12-mediated apoptosis, 
but the PrPSC-induced cytotoxicity is alleviated by overexpression of Grp58, an ER 
chaperon [40].  These findings provide the evidence that PrPSC causes ER stress and 
induces the caspase 12-mediated neuronal apoptosis in prion disease.  In addition, 
the misfolded full-length recPrP shows high neurotoxicity in vitro and in vivo, known 
as toxic prion protein (TPrP), which is in a monomeric α-helix form [41].  TPrP 
causes autophagy and apoptosis that are similar to the observation in the brain of 
prion-infected animals.  The further study indicated that TPrP causes reduction of 
intracellular nicotinamide adenine dinucleotide (NAD+) in neuronal cells, which 
decreases the production of ATP and eventually induces cells death [42].  Although 
TPrP is an artificial PrP species, it demonstrates a possibility that highly neurotoxic 
PrP monomer is created during the conformational conversion of PrPC to PrPSC. In 
addition, this PrP monomer could directly cause neuron death without the process of 
aggregation.  
 
1.1.4 Transmissible spongiform encephalopathy 
Prion disease is characterized as a neurodegenerative disorder, which causes 
clinical symptoms including dysfunction of cognition and motor.  In brain pathology, 
amyloid plaques, formed by aggregates of PrPSC, are found in animals with prion 
disease.  Also, prion disease is regarded as the propagation of infectious prions, 
which causes the death of neuronal cells and forms tiny holes in the cerebral cortex.  
Thus, prion disease is also known as transmissible spongiform encephalopathy (TSE).  
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Prion diseases have been diagnosed in several species, including scrapie in sheep, 
Kuru and CJD in humans, bovine spongiform encephalopathy (BSE) in cattle and 
chronic wasting disease (CWD) in deer (Table 1).  
Table 1. Summary of prion diseases in different species. 
Disease Host Species Route of transmission 
Kuru Human Ritualistic cannibalism 
Sporadic CJD Human Unknown etiology 
Iatrogenic CJD Human 
Accidental exposure to 
CJD-contaminated tissues 
Inherited CJD Human Mutations in Prnp gene 
Variant CJD Human Ingestion of BSE-contaminated food 
Scrapie 
Sheep, goat and 
mouflon 
Horizontal and possibly vertical 
transmission 
BSE Cattle 
Ingestion of BSE-contaminated meat 
and bone 
CWD 
Mule deer, white-tailed 
deer, Rocky mountain 
elk and moose 
Horizontal and possibly vertical 
transmission 
 
The first scrapie case was described in 1738, and the diseased sheep showed 
symptoms including aggression, tremors, incoordination and scratching [43].  
Scrapie has been found around the world, except in Australia and New Zealand, and 
this disease can only be transmitted within the flock.  In addition, PrPSC was detected 
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in milk, feces and saliva from scrapie-infected sheep, which indicated scrapie may be 
transmitted through these scrapie-contaminated agents [44-46].  In 1998, five cases 
of atypical scrapie were described in Norway, which was named as Nor98 [47].  In 
these animals, PrPSC was only found in the cortex of the cerebrum and the cerebellum, 
but not in the lymphoid tissue.  Although atypical scrapie has been found in many 
countries, including New Zealand; in each case, only a few animals were diagnosed as 
the prion disease in the same cluster [48].  These observations support that atypical 
scrapie is poorly transmitted, but the pathogenesis of this disease remains unclear. 
In 1980, the CWD of deer and elk was identified in Colorado and Wyoming, 
and symptoms included emaciation, excess rumen fluid and spongiform 
transformation in the central nervous system (CNS) [49].  To date, CWD has only 
been found in the United States, Canada and South Korea.  CWD can be transmitted 
through saliva, blood and feces to other healthy deer, but the disease origin is still 
unclear [50-52].  The major concern is whether CWD can be transmitted to other 
species, especially humans.  By oral inoculation, CWD has not been transmitted to 
other species outside of the cervid family [53].  However, transgenic mice with 
expression of elk or deer PrPC develop prion disease after inoculation with the brain 
from CWD-infected animals, but the disease is not found in transgenic mice 
expressing human, ovine or bovine PrPC [54, 55].  An in vitro study showed that 
CWD-associated PrPSC was less efficient to convert bovine or human recPrP into 
PrPSC, comparing with cervid recPrP [56].  These studies indicated there is a strong 
species barrier for CWD transmission.  In addition, no large-scale of human prion 
disease has been reported in Colorado and Wyoming for the past three decades, which 
supports that CWD is not transmitted to humans [57]. 
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In 1986, an epidemic of spongiform encephalopathy was identified in cattle in 
the United Kingdom, known as BSE or “mad cow” [58].  BSE is classified as a prion 
disease, because PrPSC is found in the brain from diseased cattle [59].  More than 
35,000 cattle were diagnosed in 1992, which reached the peak of BSE infection 
(Figure 3A).  The large-scale outbreak of BSE is attributed to feeding of 
BSE-contaminated meat and bone as supplement to cattle [60].  In 2003, another 
peak of BSE cases occurred mainly in France and Ireland, and this outbreak of BSE 
was well-controlled.  In last 5 years, no more than 30 cases of BSE per year were 
reported worldwide.  Although the epidemic of BES is well-controlled, it has still 
not been eradicated.  Can BSE be transmitted to humans?  An in vivo study 
demonstrated that non-human primates receiving oral inoculation of the brain from 
BSE-infected cattle developed prion disease [61].  The PrPSC from BSE-infected and 
vCJD-infected mice showed undistinguishable glycosylated pattern, suggesting that 
BSE and vCJD are caused by the same prion strain [62].  In addition, based on the 
cases of BSE and variant CJD (vCJD) in the UK, it shows that the outbreak of vCJD 
correlates with the prevalence of BSE in 1992 (Figure 3B).  These pieces of 
evidence support the notion that BSE can be transmitted to humans and develop 
vCJD. 
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Figure 3. Annual cases of bovine spongiform encephalopathy (BSE) reported 
worldwide and variant Creutzfeldt-Jakob disease (vCJD) in the United Kingdom 
(UK).  (A) The cases of BSE in the UK (black) and in countries excluding the UK 
(red).  The peak in early 2000s majorly occurred in France and Ireland.  Data are 
updated on April 2015 (http://www.cjd.ed.ac.uk).  (B) The cases of BSE (black) and 
vCJD (red) in the UK.  Data are updated in April 2015 (http://www.oie.int).  
   
Kuru, a human transmissible spongiform encephalopathy, was reported in the 
region of Papua New Guinea in 1950s, and transmission of disease was imputed by 
ritualistic cannibalism [63].  CJD is classified into four types, including variant, 
iatrogenic, inherited and sporadic. Variant CJD was first identified in 1996 and is 
linked to BSE.  Iatrogenic CJD is an accidental transmission from other CJD patients 
during surgical procedures [64].  Also, several cases were from receiving human 
growth hormone or pituitary gonadotropins derived from CJD patients [65-68].  
Inherited CJD is due to alteration of Prnp gene, which includes familial CJD (fCJD), 
Gerstmann- Sträussler-Scheinker disease (GSS) and fatal familial insomnia (FFI).  
fCJD is associated with the point mutation at codon 145 of Prnp gene that creates the 
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premature stop codon, which generates the deposition of PrP and Tau protein [69, 70].  
Also, fCJD is characterized by rapid progression of dementia.  GSS is a rare 
inherited and slow progressive disease, which is caused by the mutation in codons 
P102L and F198S of Prnp gene [71].  The point mutation of D178N of Prnp gene 
causes FFI which is characterized by refractory insomnia and dysautonomia [72].  
Sporadic CJD (sCJD) accounts for 85% of human prion diseases.  In sCJD patients, 
there is no mutant Prnp allele, nor evidence for contact with infected patients or 
animals.  The polymorphism of codon 129 of Prnp gene (methionine/valine) has a 
strong correlation with sCJD.  Clinical studies showed 21 out of 22 sCJD cases were 
homozygous at codon 129 of Prnp gene [73].  However, the pathogenesis of sCJD 
remains elusive.   
 
1.2 Transmission Pathway of Prion Disease 
1.2.1 Natural route of prion disease transmission 
  The cases of Kuru and vCJD illustrate that the natural route of the prion 
disease pathogenesis is through oral exposure.  This transmission route is confirmed 
by the following studies.  Oral inoculation of brain homogenates from animals 
infected with scrapie or BSE caused the development of the prion disease in sheep 
and mice [74, 75].  Also, CWD can be transmitted via oral route between deer [76, 
77].   
How is PrPSC transported from the lumen of the gastrointestinal tract to 
lymphoid tissues?  Microfold cells (M cells) take up particulate antigens from the 
gut lumen and transport it to Peyer’s patches to stimulate the adaptive immune 
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response.  In order to study the transportation of PrPSC by M cells, a device was 
designed that contained a filter seeded with Caco-2 cells and Raji B cells, placed on 
another side [78].  The B cells can migrate through the filter and promote Caco-2 
cells to differentiate into M cells.  This study showed that the M cells containing 
cocultures transported the prion protein to the basolateral chamber, but Caco-2 
cultures did not transfer prion to the other side.  Mice with depletion of M cells 
decrease the early accumulation of PrPSC in Peyer’s patches and further neuroinvasion 
[79].  Both studies indicated that M cells are important for transporting the prion 
protein from the gut lumen to Peyer’s patches (Figure 4). 
 
 
Figure 4. Summary of the oral route of PrPSC transmission.  PrPSC is transported 
by microfold cells (M cells) from gut lumen into the Peyer’s patch.  CD11c+ 
dendritic cells (DCs) receive PrPSC from M cells and migrate to lymphoid follicle 
where PrPSC is delivered to FDC.  PrPSC replicates on the plasma membrane of 
follicular dendritic cells (FDCs), and PrPSC undergo a retrograde neuroinvasion 
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through afferent autonomic nervous system; eventually, PrPSC reaches central nervous 
system. 
 
Who receives PrPSC from M cells and spreads it to lymphoid tissues?  The 
rats treated with scrapie-associated fibrils, highly infective aggregates of PrPSC, 
showed that migratory dendritic cells (DCs) were a carrier of PrPSC, but not T or B 
lymphocytes [80].  Exposing CD11c+ myeloid DCs to scrapie infected GT1-1 cells, 
CD11c+ DCs engulfed infected GT1-1 cells, but PrPSC was degraded by the cysteine 
protease [81, 82].  In an oral inoculation study using the brain homogenate from 
scrapie-infect animals, CD11c+ DC-depleted mice showed a blockade of prion protein 
accumulated in lymphoid tissues and a decrease of susceptibility to the disease [83].  
Although previous studies showed that PrPSC was degraded in CD11c+ DCs, the in 
vivo study indicated CD11c+ DCs play an important role in spreading PrPSC. 
 
1.2.2 Accumulation of PrPSC in lymphoid tissues 
In CJD-infected mice, CWD deer and scrapie sheep, accumulation of PrPSC was 
detected in lymphoid tissues, e.g., lymph nodes, spleen, palatine tonsils and Peyer’s 
patches in the early stage of disease progression [76, 84-86].  The results of an 
immunohistochemical study indicated that two kinds of cells highly expressing PrPC 
in lymphatic system are follicular dendrite cells (FDCs) and DCs [87].  Confocal 
microscopy analysis showed the colocalization of FDCs and PrPC in uninfected 
mouse spleen tissue [86].  FDCs are long-lived and non-migratory cells in primary 
and secondary follicles.  Also, FDCs provide long-lasting intact antigens for 
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receptors on B cells in the germinal center.  The immuno-electron microscopy study 
showed accumulation of PrPSC was on the FDCs plasma membrane and intracellular 
space [88].  This report also showed that tangible-body macrophages received PrPSC 
from FDCs, which facilitated the transportation of PrPSC in the lymph system.  There 
are two different ways for FDCs to hold PrPSC on cell surface (Figure 5).  First, the 
PrPC on the plasmas membrane of FDCs interacts with PrPsc to form an oligomer.  
Second, complement receptors (CD21 and CD35) on the surface of FDCs bind to 
complement-PrPSC complexes.  The susceptibility to the prion disease from 
peripheral infection was reduced in both C3/C1q-/- mice and CD21/CD35-/- mice 
[89-91]. 
 
Figure 5. Maturation of FDC and PrPSC presenting on FDC.  PrPSC is presented 
on FDC through PrPC, complement C1q-CD35 and complement C3-CD21.  The 
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presenting PrPSC is engulfed by macrophages.  The maturation of follicular dendritic 
cell (FDC) is achieved by B cell-dependent tumor-necrosis factor α (TNF-α) and 
lymphotoxin β in secondary lymphoid follicles. 
 
Although PrPC expression on B cells is not necessary and not sufficient for 
PrPSC propagation [92, 93], B cells play an important role in promoting the maturation 
of FDCs through tumor-necrosis factor α (TNF-α) and lymphotoxin β (Figure 5).  In 
vivo studies showed that TNF-α-knockout mice were resistant to peripheral prion 
infection [94, 95].  Blockade of TNF-α receptors by antibody showed the temporary 
inhibition of PrPSC spread [96].  In peripheral inoculation studies, impedance of the 
lymphotoxin β signaling pathway reduced the susceptibility of the prion disease and 
decreased the accumulation of PrPSC in the spleen [97-99].  However, through 
intracerebral inoculation, it did not change prion disease pathogenesis [100].  These 
findings further supported that matured FDCs are the crucial player in propagating 
PrPSC from peripheral tissues to CNS, but other immune characteristics, e.g., B 
lymphocytes and complement components, are also required.  Although suppression 
of FDCs maturation could reduce the spread of PrPSC, it was only efficient during the 
early stage of the disease progression [101].  Numerous autonomic nerves are 
located in or near secondary lymphoid tissues, and the accumulated PrPSC undergoes a 
retrograde neuroinvasion through these nerves to reach CNS. 
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1.2.3 From peripheral tissues to central nerve system 
In hamsters infected with the scrapie protein orally, PrPSC was found in 
myenteric and submucosal plexuses on day 69 post-inoculation (dpi).  In addition, it 
was found in mesenteric lymph nodes, mucosal lymphoid follicles and Peyer’s 
patches [102].  At 76 dpi, PrPSC was abundant in the ganglia of the enteric nervous 
system and the associated nerve fibers.  In BSE-infected cattle, PrPSC was found in 
the vagus nerve and coeliac mesenteric ganglion complex [103].  In vCJD patients, 
immunochemical analysis showed that PrPSC was accumulated at celiac ganglia and 
stellate ganglia [104].  Animals receiving oral inoculation of brain homogenate from 
animals with PrPCS showed that PrPSC appeared in the sympathetic nerve system 
[105-107].  Chemical sympathectomy in mice was achieved by injection of 
6-hydroxydopamine and anti-nerve growth factor antibody, these mice showed a 
blockade or delay of prion disease progression [108].  On the other hand, keratin 
14-nerve growth factor transgenic mice, which had hyperinnervated sympathetic 
nerves at lymphoid tissues, showed higher susceptibility to the prion disease.  Above 
studies demonstrated that sympathetic nerves, parasympathetic nerves and associated 
fibers were possible routes for transferring PrPSC from peripheral tissues to CNS. 
How do cells transfer pathogenic prion protein to other cells?  Although the 
mechanism details are not fully understood, several hypotheses have been proposed.  
Non-infected cells release PrPC into culture medium via membrane vesicles; similar 
results were found in PrPSC-infected cells in which PrPSC was released into medium 
through exosome-like vesicles [109].  Tunneling nanotube (TNT) is a thin tube used 
by cells to communicate with other cells over a long distance.  In mouse neuronal 
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cells, membranous and endogenous PrPSC are transferred from infected cells to naive 
cells by TNTs.  Also, bone marrow-derived DCs can interact with the primary 
neuron and transfer PrPSC by TNTs in vitro [110].  When analyzing non-fibrillar 
particles of the scrapie-infected hamster brain, it was found that these particles had 
14-28 prion protein molecules, being the most efficient seed for the prion disease 
[111].  Based on this evidence, a free-floating PrPSC model was proposed.  Once 
pathogenic PrP reaches the spinal cord via the peripheral nerve system, it traverses in 
a retrograde direction to brain and forms the aggregate. 
 
1.3 Methods for Detection of Prion Disease 
The traditional methods to diagnose prion disease are through post-mortem 
immunohistochemical and neuropathological examinations, and they are still the most 
reliable assays for prion disease [112].  In recent years, several assays were 
developed for preclinical diagnosis of prion diseases using accessible body fluids, 
such as plasma and saliva. 
1.3.1 Bioassays  
In 1982, the animal bioassay of PrPSC was established, and Syrian hamsters 
were used in this assay [113].  Syrian hamster is highly susceptible to prion disease 
through intracerebral inoculation of the brain tissue from scrapie-infected sheep.  
The time from inoculation to onset of symptoms or to death is inversely proportional 
to the dose of intracerebral injection of the scrapie-infected brain homogenate.  
However, this assay is time-consuming, costly and imprecise to determine the prion 
infectivity in brain sample.  An improved bioassay was developed by using N2a 
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neuroblastoma cells that are susceptible to PrPSC from scrapie-infected mice [114].  
N2a cells are transferred to the membranes of enzyme-linked immunospot (ELSPOT) 
plates, and they go through lysis, proteinase K digestion and detection by PrP 
antibody.  The number of PrPSC-infected colonies is strongly correlated with the dose 
of the brain homogenate from scrapie-infected mice.  Comparing with the hamster 
assay, N2a cells assay is ten times faster and less expensive.  
 
1.3.2 Protein-misfolding cyclic amplification 
According to the “seeded nucleation” model, the method of amplification of 
misfolded prion protein was established, known as protein-misfolding cyclic 
amplification (PMCA) [115].  PrPSC from scrapie-infected hamster brain serves as 
seeds, and the raw material, PrPC, is provided by health hamster brain.  The 
amplifying reaction is accelerated by sonication that breaks up aggregates and 
produces more seeds for PrP conversion.  Through western blot analysis, 
concentrations of PrPSC in samples are estimated.  After five PMCA cycles, more 
than 97% of PrPSC becomes the newly converted protein.  In addition, the amplified 
PrPSC shows infectivity in hamsters [116].  Raw materials for PMCA are not only 
provided by brain homogenate, but also by hamster recPrP that decreases the 
sensitivity of PrPSC assay [117].  The PMCA assay is widely used for different 
samples from animals with prion disease, including brain, blood, feces, urine and milk 
[118-121].  In scrapie-infected hamsters, PrPSC concentrations are 2.3 × 10g/g in 
brain, 2.0 × 10		g/g in spleen and 1.3 × 10	
g/ml in plasma [122]. 
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Although PrPSC can be detected in blood samples by PMCA, it is still 
problematic.  In order to amplify the PrPSC from blood, more PMCA cycles are 
repeated over several days, which increases false positive results.  Surround optical 
fiber immunoassay (SOFIA) is comprised of a set of monoclonal antibodies and the 
comprehensive high-energy fluorescence emission is measured.  In the prototype of 
SOFIA, extraction of PrPSC from the brain sample is achieved by digestion with 
proteinase K, and the detection limit is around 10-17 g of PrPSC from scrapie-infected 
hamster brains [123, 124].  When limited serial PMCA and SOFIA are combined, it 
ameliorates the problem of high false positives and PrPSC is detected in proteinase 
K-untreated plasma samples from scrapie-infected sheep and CWD-infected 
white-tailed deer [125].  However, due to the non-standardized instrument in SOFIA, 
this assay is difficult to be widely used for PrPSC detection. 
 
1.3.3 Quaking-induced conversion 
Samples may receive different vibrational energy in PMCA, resulting from tube 
position, tube construction and type of sonicator.  These factors make the process of 
sonication difficult to standardize, and affect the consistency of PMCA assay.  In 
order to ameliorate the problem of sonication, periodic shaking substitutes the process 
of sonication in a new technique known as quaking-induced conversion (QuIC) [126].  
Through the QuIC assay, samples, such as brain tissue and cerebral spinal fluid (CSF), 
from vCJD patients or scrapie-infected sheep were discriminated within 1-2 days 
[127].  Thioflavin T, a fluorescent emission dye, binds to the β-sheet-rich structure, 
such as amyloid aggregates [128, 129].  The amount of PrPSC is quantified by 
 22
measuring the fluorescent intensity instead of the western blot analysis.  This method 
provides the real-time information of PrPSC conversion; therefore, it is named 
real-time QuIC (RT-QuIC) [130].  PrPSC in brain tissue, CSF and nasal fluids were 
detected by RT-QuIC, but it cannot be used to analyze blood samples due to the low 
sensitivity [130-132].  Monoclonal 15B3 antibody is the PrPSC 
conformational-specific antibody, and its epitope corresponds to residues 142-148, 
162-170 and 214-226 of human PrP [133].  Through combination of the PrPSC 
immunoprecipitation by 15B3 mAb and RT-QuIC, plasma or serum samples from 
scrapie-infected hamster were distinguished from health hamster (Figure 6) [134].   
 
Figure 6. Mechanism of using immunoprecipitation and QuIC to detect PrPSC.  
PrPSC is pulled out from blood samples by 15B3 mAb, and the recPrP is added.  
Based on the “seed nucleation” model, recPrP is slowly converted into PrPSC and 
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aggregates with PrPSC.  Shaking the tube causes the fragmentation of PrPSC 
aggregates which produce more seeds known as secondary seeds.  More seeds will 
provide a dock for newly converted PrPSC which promotes the production of PrPSC. 
 
1.3.4 Extraction of PrPSC by stainless steel 
In addition to the PrPSC immunoprecipitation method, stainless steel is also used 
to extract PrPSC from blood samples.  The study of iatrogenic CJD showed PrPSC 
was transmitted through contaminated stainless steel surgical instruments [64, 135].  
Further study showed that PrPSC bond to nickel and molybdenum powder with high 
affinity [136].  Detection of PrPSC in blood samples can be achieved by extracting 
PrPSC with particles of stainless steel and measured by PrP enzyme-linked 
immunosorbent assay (ELISA) [137].  The blood samples from vCJD patients were 
distinguished by this assay [138].  More importantly, this method does not require 
amplification of PrPSC through PMCA or QuIC, so it reduces the rate of false positive.  
However, this method showed 28.6% false negative due to low amount of PrPSC in the 
sample [138].  
 
1.3.5 Perspectives 
Due to low solubility, the concentration of PrPSC maybe rather low in body 
fluids.  Although PrPSC can be detected through the process of amplification or 
extraction, these assays showed a large number of false positives and false negatives.  
To avoid these false results, novel methods are needed to analyze body fluids, such as 
plasma to help with diagnosis of prion diseases.  Based on the concept of PrPSC 
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replication, PrPC is converted into PrPSC during the progression of prion disease.  
Thus, it is hypothesized that PrPC is diminished in animals with prion disease.  Here, 
we developed a radioimmunoassay to detect PrPC in plasma.  It is hope that this 
assay will be useful in the diagnosis of scrapie and CWD. 
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CHAPTER 2 
DEVELOPMENT OF A RADIOIMMUNOASSAY FOR SCREENING OF PRION 
DISEASES 
 
2.1 Abstract 
The main challenge in the diagnosis of prion disease in animals is the lack of a 
reliable preclinical assay.  Current assays using plasma samples through 
amplification or extraction of proteinase K-resistant prion protein (PrPSC) face a 
problem of high false-results rate, because of the low concentrations of PrPSC in 
plasma samples.  In this report, we described the development of radioimmunoassay 
(RIA) of cellular prion protein (PrPC) by using 125I-labeled residue 143-153 of prion 
protein (125I-PrP143-153).  This assay could detect prion protein (PrP) fragments in 
brain homogenate and plasma sample from healthy sheep.  Using RIA, the 
concentration of PrP143-153 was determined as 0.29 μg/g total proteins in a brain 
homogenate, and 99 pg/ml in a plasma sample.  The detection limit of this assay was 
31 pg/ml, and the intra- and inter-assay variabilities were <10%.  This assay may 
have a potential to be used for diagnosis of scrapie in sheep and chronic wasting 
disease (CWD) in cervids.  The animals with prion disease are expected to have 
lower plasma concentrations of PrP143-153 than normal animals.  This hypothesis will 
be tested in future studies. 
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2.2 Introduction 
Prion disease is a transmissible neurodegenerative disease with slow 
progression.  Misfolded prion proteins (PrPSC) are regarded as infectious agents and 
biomarker of prion disease.  PrPSC replicates in the cells with high concentration of 
cellular prion protein (PrPC), such as neuronal cells, and forms aggregates, known as 
amyloid.  The disease with aggregates of PrPSC causes the death of neurons and 
forms tiny holes in cerebral cortex.  Thus, prion disease is also known as 
transmissible spongiform encephalopathy (TSE).  Prion disease has been found in 
several species, including scrapie in sheep and goats, Creutzfeldt-Jakob disease (CJD) 
in humans, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting 
disease (CWD) in cervids. 
In 1947, the first case of scrapie was found in the United States, and most of 
scrapie cases are only transmitted within the flock.  Although there is no large 
outbreak of scrapie in the United States, sporadic reports of scrapie indicate loss of 
export sales which cost producers $20 million per year [1].  In order to eradicate 
scrapie in the United States, it requires reliable assays for large-scale surveillance.  
CWD is found in several geographic areas of the United States, especially 
northeastern Colorado and southeastern Wyoming.  A previous study showed 
Suffolk sheep developed CWD after receiving intracerebral inoculation of brain 
homogenate from CWD-infected mule deer [2].  Thus, it is still a concern that CWD 
could be transmitted to other species, especially sheep.   
PrPSC is detected in milk, feces and saliva from scrapie-infected sheep [3-5], 
and it is found in saliva, blood and feces from CWD-infected cervids [6-8].  These 
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body fluids and excreta could be used for diagnosis of prion disease.  In recent years, 
the low amount of PrPSC in plasma samples was detected by following methods.  
First, PrPSC is amplified by protein misfolding cyclic amplification (PMCA) and 
detected by the surround optical fiber immunoassay (SOFIA) [9, 10].  Second, PrPSC 
in plasma is extracted by PrPSC-specific antibody, and then purified PrPSC is amplified 
and detected by real time quaking-induced conversion (RT-QuIC) [11, 12].  However, 
the process of amplifying PrPSC results in a high false positive rate and the assay 
procedures are complicated.  Third, PrPSC in plasma is extracted by stainless steel 
and the concentration of purified PrPSC is measured by ELISA [13, 14].  However, 
the false negative rate in this assay is 28.6% [13]. 
Shed PrPC and PrPC fragments in extracellular fluid are released from cells 
surface through the cleavage of glycosylphosphatidylinositol (GPI)-anchor on PrPC by 
a-disintegrin-and-metalloproteinase 10 (ADAM10) [15, 16]. 
The objective of the present study was to develop a radioimmunoassay (RIA) to 
detect the plasma concentrations of PrPC in both normal animals and animals infected 
with scrapie or CWD.  In future studies, we will determine whether there is a 
difference between normal and diseased animals with regard to plasma concentrations 
of the prion protein. 
 
2.3 Materials and Methods 
Materials 
Chemicals and their sources are stated as follows: synthetic human residue 
143-153 (human PrP143-153), SDYEDRYYREN and synthetic ovine residue 143-153 
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(ovine PrP143-153), NDYEDRYYREN (Protein Facility, Iowa State University, IA); 
ovine recombinant prion protein (recPrP) (Abcam, Cambridge, MA); Na125I and 
Packard Cobra γ counter 5002 (PerkinElmer, Boston, MA); goat anti-PrP143-153 
antibody (Aviva Systems Biology, San Diego, CA & GeneTex, Irvine, CA); 6H4 
monoclonal antibody (mAb) (Prionics, Switzerland); POM1 mAb (Prionatis AG, 
Switzerland); chloramine-T, n-octyl-glucoside, 2-(N-morpholino)ethanesulfonic acid 
(MES), and phenylmethylsulfonylfluoride (PMSF) (Acros Organics, Belgium); G-25 
Sephadex, sodium metabisulfite (Sigma-Aldrich, St. Louis, MO); BCA protein assay 
(Pierce, Rockford, IL); polyethylene glycol (PEG) 8000 (Fisher Scientific, Pittsburg, 
PA). 
Iodination and purification of recPrP and PrP143-153 
Iodination and purification of recPrP 
Five μg of ovine recPrP was dissolved in 30 μl 0.1 M phosphate buffer (pH 7.1) 
with 0.1% triton X-100, and 1 mCi Na125I was added.  Iodination reaction was 
initiated by adding 10 μl of 0.4 mg/ml chloramine-T.  After 4 min, 20 μl of 0.2 
mg/ml sodium metabisulfite was added to stop the reaction.  The iodinated mixture 
was loaded into a G-25 Sephadex column, and eluted by 0.1 M phosphate buffer (pH 
7.1) with 0.1% triton X-100 at room temperature.  One-ml fractions were collected, 
and 3 μl aliquots were counted by Packard Cobra γ counter 5002.  The 125I-recPrP 
appeared in fraction 4, which was stored at 4°C. 
Iodination and purification of PrP143-153 
Two μg of synthetic human PrP143-153 was dissolved in 10 μl of 0.5 M phosphate 
buffer (pH 7.5).  One mCi Na125I was added to solution, and iodination reaction was 
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initiated by adding 10 μl of 1 mg/ml chloramine-T.  After 1 min of reaction, 100 μl 
of 100 mg/ml bovine serum albumin (BSA) in 0.1 M acetic acid was added to quench 
surplus 125I.  The iodinated mixture was loaded into a G-25 Sephadex column, and 
column was eluted by 0.1 M acetic acid with 0.1% BSA at 4°C.  One-ml fractions 
were collected, and 125I-PrP143-153 appeared in fractions 15-20.  The 125I-PrP143-153 
was stored at 4 ℃. 
Homogenization of ovine brain tissue and collection of ovine plasma 
Ovine brain tissues (10% w/v) were homogenized by Tissumizer SDT-1810 
(Tekmar, Cincinnati, OH) on ice in 25 mM MES (pH 6.5), 150 mM NaCl, 1% triton 
X-100, 60 mM n-octyl-glucoside, 10 mM PMSF and 1mM EDTA.  To remove 
debris, the homogenate was centrifuged at 3090 X g for 30 min at 4°C.  Supernatants 
were collected and stored at -20°C.  The protein concentration in brain homogenate 
was determined by BCA protein assay.  Ovine blood samples were collected with 
0.2% EDTA and placed on ice.  Blood samples were centrifuged at 1373 X g for 20 
min at 4°C.  Plasma was collected and stored at -20°C.   
Radioimmunoassay 
Radioimmunoassay of recPrP 
Polyethylene tubes were used for the assay.  One hundred μl of recPrP solution 
was incubated with 1:10000 POM1 mAb in 0.1 M phosphate buffer (pH 7.5), 0.2% 
BSA, 0.1% NaN3 at 4°C for overnight.  Then, 100 μl of 125I-recPrP (30,000 cpm) 
was added to tubes and incubated for overnight.  Next day, 1:40 anti-mouse antibody 
and 1:80 mouse serum were added to each assay tube, and tubes were incubated for 
another 30 min at 4°C.  One hundred μl of horse serum and 1 ml 12% PEG 8000 in 
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0.85% NaCl were added before centrifugation at 3090 X g for 30 min at 4°C.  
Supernatants were removed, and pellets were counted by Packard Cobra γ counter 
5002. 
Radioimmunoassay of PrP143-153 
One hundred μl of ovine brain homogenate or ovine plasma was incubated with 
100 μl of 1:4000 goat anti-PrP143-153 antibody (0.5 mg/ml stock) in 0.1 M phosphate 
buffer (pH7.5), 0.2% BSA, 0.1% NaN3 and 2 mM EDTA at 4°C for overnight.  Then, 
100 μl of 125I-PrP143-153 (30,000 cpm) was added and incubated for overnight.  On 
the third day, 100 μl of 1:20 donkey anti-goat antibody and 100 μl of 1:40 ovine 
plasma were added to each assay tube, and tubes were incubated for 30 min at 4°C.  
One hundred μl of horse serum and 1 ml of 12% PEG 8000 in 0.85% NaCl were 
added to each assay tube immediately before centrifugation at 3090 X g for 30 min at 
4°C.  In the assay of ovine plasma, on the third day, 100 μl of 1:20 donkey anti-goat 
antibody and 100 μl of ovine plasma were added and tubes were incubated for 5 min 
at 4°C.  Then, 1 ml of 12% PEG 8000 in 0.85% NaCl was added and centrifuged at 
3090 X g for 30 min at 4°C.  Supernatants were removed and pellets were counted 
by Packard Cobra γ counter 5002.  The standard curve was set up using synthetic 
PrP143-153. 
Digestion of prion protein with proteinase K 
Ovine brain homogenates were incubated with 0.6, 1.9, 5.6 μg/ml proteinase K 
in 50 mM Tris buffer (pH 8.0) and 10 mM CaCl2 at 60°C for 1 hr.  The reactions 
were terminated by adding 10 mM PMSF in isopropanol, and samples were stored at 
4°C.  
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Data Analysis 
% Bound was calculated by cpm in the pellet over the total cpm.  The standard 
curve was composed of X: ln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/, and it was fit by the linear regression.  
 
2.4 Results 
We attempted to establish the RIA of recPrP in the early stage of the research; 
we intended to label recPrP with 125I and purify the 125I-recPrP.  125I-recPrP 
interacted with POM1 mAb, and the displacement by recPrP was detected.  However, 
it was not practical to use 125I-recPrP as a tracer in RIA due to two reasons:  First, the 
specific binding was 14.9%, but the non-specific binding was 34.3%.  Second, the 
life span of the tracer was only a week.   These two problems might be caused by 
the aggregation of recPrP.  To avoid the problem of aggregation, we looked for a 
region in PrP instead of the full-length of PrP as the tracer candidate.  We prepared 
PrP143-153 as the tracer in RIA because of following four reasons:  First, the internal 
region 143-153 is the first α-helix in the globular structure of PrP, and this structure is 
not imbedded in the globular structure (Figure 1A-D).  Second, this sequence is 
highly conserved in different species (Figure 1F).  In human and cervid/ovine 
PrP143-153, there is only one amino acid difference in the sequence.  Thus, the RIA of 
PrP143-153 was developed to assay the samples from different species.  Third, there 
are three commercial antibodies against this region.  6H4 mAb is against residue 
144-152 of human PrP (DYEDRYYRE) [17].  The pair-wise mapping study 
indicated that POM1 mAb shares the similar epitope with 6H4 mAb [18].  The goat 
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anti-PrP143-153 antibody used in this study was raised in a goat against synthetic 
PrP143-153 (SDYEDRYYREN).  Fourth, tyrosine is required for iodination of peptides, 
and there are three molecules of tyrosine in this region.  
 
 
Figure 1. (A-E) The globular structure of ovine prion protein.  The red region is 
the first α-helix structure with the sequence of SDYEDRYYREN. (F) The residues of 
PrP145-153 in different species; the sequence of human PrP is based on NCBI protein 
database, NP_000302.1. 
 
The synthetic human PrP143-153 was iodinated by 125I, and surplus 125I was 
quenched by BSA (100 mg/ml) that prevented it from reacting with PrP143-153.  
Through antibody binding test, it was found that fraction 5 contained BSA, fractions 
(A)             (B)            (C)            (D)             (E)
(F) Human: S D Y D R Y Y R N
Bovine: . . . . . . . . .
Pig: . . . . . . . . .
Deer: N . . . . . . . .
Ovine: N . . . . . . . .
Mouse: N . W . . . . . .
Hamster: N . W . . . . . .
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11-12 contained free 125I and fractions 15-20 contained 125I-PrP143-153 (Figure 2A).  
Fraction 16 had the highest binding by anti-PrP143-153 antibody.  Unexpectedly, 
125I-PrP143-153 did not interact with either 6H4 mAb or POM1 mAb (data not shown).  
Because of the difference in first N-terminal amino acid between human and ovine 
PrP143-153, it might cause a different interaction between PrP143-153 and anti-PrP143-153 
antibody.  In order to understand whether anti-PrP143-153 antibody could distinguish 
the difference, we used both human PrP143-153 and ovine PrP143-153 to set standard 
curves in this RIA (Figure 2B).  The result showed there was no difference between 
two standard curves, which indicated that this RIA does not distinguish human 
PrP143-153 and ovine PrP143-153.   
Ovine recPrP was used to compete with the tracer, but there was no competition.  
In other words, recPrP was not detected by the RIA of PrP143-153, and thus this RIA 
could not be used to detect recPrP.  However, the serial dilution of ovine brain 
homogenate showed the parallelism with the standard curve of PrP143-153 in the 
antibody binding activity (Figure 2C).  Also, the standard curve of PrP143-153 showed 
that detection limit of the RIA was 31 pg/ml and R2 was >0.99.  The RIA did not 
detect recPrP, but “something” was detected in the ovine brain homogenate by this 
assay.  Because the molecular weight of full-length PrP is 23 times larger than 
125I-PrP143-153, full-length PrP might be difficult to compete with the tracer.  Our 
results suggested that the brain homogenate contains not only intact PrP but also the 
fragments of PrPC that can compete with the tracer on the antibody against PrP143-153.  
We speculate that “something” is the fragments of PrPC.   
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The RIA was validated by the homogenate of ovine brain (Table 1).  The 
inter-assay variability was 7%, and the recovery was 105%.  The intra-assay 
variability was 7-10%, and the PrPC fragments in ovine brain samples was 0.29 μg/g 
total proteins. 
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Figure 2. Purification of 125I-PrP143-153 and parallelism between the standard 
curve and serial dilutions of ovine brain samples.  (A) Iodinated mixture was 
purified by Sephadex G-25 column, and 3 μl aliquots were counted.  (B) Standards 
of 48 to 760 pg/ml human PrP143-153 (■) and standards of 63 to 1000 pg/ml ovine 
PrP143-153 (●).  (C) 1:1 serial dilution of ovine brain homogenates yield binding 
results that paralleled with those of the standard curve of PrP143-153.  Standards of 
115 to 920 pg/ml PrP143-153 were used (■), two independent curves of ovine brain 
homogenates diluted from 1:5 to 1:80, and the curves shifted horizontally (●) (▲).  
Each value represents the data from duplicates of an independent RIA. 
 
Table 1. 920 pg/ml PrP143-153 was used as a reference standard that was repeated 5 
times to calculate inter-assay variability and recovery.  Samples were ovine brain 
homogenate being diluted 1:8, and each sample was assayed 4 times to calculate 
intra-assay variability and mean concentration of PrPC fragment in an ovine brain 
homogenate.  Each value represents the repeat of the reference standard samples 
from duplicates of the RIA.  Coefficient of variation (CV) = standard 
deviation/mean.  
Validation of the RIA 
 
Average Recovery CV
969.6 1023.8 843.7 988.2 987.1 962.5 104.62% 7.19%
Average CV
286.3 251.1 308.9 273.6 280.0 8.64%
383.7 345.1 385.5 413.2 381.9 7.32%
280.6 254.8 285.7 326.2 286.8 10.3%
509.8 520.4 500.8 579.4 527.6 6.72%
Intra-assay Variation
Sample
Inter-assay Variation
Reference (920 pg/ml)
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In order to confirm the hypothesis that this RIA could only detect PrPC 
fragments containing PrP143-153 instead of intact PrPC, the brain homogenate (9.1 mg 
protein/ml) was pretreated with proteinase K that is widely used to digest PrPC.  The 
ovine brain homogenates were digested by 0.6, 1.9 and 5.6 μg/ml proteinase K at 
60°C for 1 hr, which showed lower % bound than control group in the RIA (Figure 
3A).  These results demonstrated that the digestion by proteinase K released the 
fragments from intact PrPC, and these fragments were able to compete with the tracer 
for the antibody binding.  Moreover, the amount of proteinase K-released fragments 
was proportional to the dose of proteinase K.  The dose-dependency of proteinase K 
further supported the hypothesis that only fragments containing PrP143-153 could be 
detected in this RIA.   
 
 
Figure 3. Pretreatment of ovine brain homogenate with proteinase K releases 
PrPC fragments from intact protein.  Ovine brain homogenate was treated with 0.6, 
1.9 and 5.6 μg/ml proteinase K for 1hr at 60°C, and reaction was terminated by 10 
mM PMSF. 
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Through RIA, the concentration of fragments containing PrP143-153 in ovine 
plasma samples was detected as 99 ± 9.7 pg/ml.  In order to know whether other 
components in plasma distorted the RIA, we used standard addition method to test.  
The plasma samples were spiked with 24, 48, 95, 190 and 380 pg/ml analyte 
(PrP143-153).  The curve of spiked plasma samples paralleled with the standard curve 
of PrP143-153, which indicated that there were no interferents in plasma samples to 
affect the RIA (Figure 4A).  In addition, the concentration of PrPC fragments in 
plasma was equal to the difference between observed concentration and analyte 
concentration.  The mean of differences was 118 pg/ml (Table 2).  This value was 
similar to that of unspiked ovine plasma sample (99 pg/ml), which indicated the 
concentration of PrPC fragments in the plasma sample was ~108 pg/ml.  Based on 
the results of measurement of unspiked samples and standard addition method, we 
concluded that the RIA could detect the PrPC fragments containing PrP143-153 in 
plasma samples.  
 In order to explore how fast peptides are degraded in plasma samples with 
0.2% EDTA, we added the 920 pg/ml PrP143-153 standard to ovine plasma and 
incubated it at 37°C.  Samples were collected at each time point and stored at 4°C 
until assay.  Comparing with 0 min, the concentration of PrP143-153 was 97.7% at 3 hr 
incubation, 92.6% at 6 hr, 85.9% at 12 hr and 77.4% at 24 hr (Figure 4B).  This 
result suggested that PrP143-153 is stable in plasma, and thus the plasma samples for the 
RIA are well-preserved when 0.2% EDTA is used as the anticoagulant. 
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Figure 4. Ovine plasma spiked with PrP143-153 and degradation of PrP143-153 in 
ovine plasma.  (A) The parallelism between the standard curve of PrP143-153 and the 
serially diluted ovine plasma samples spiked with PrP143-153.  Standard curve of 24 to 
760 pg/ml PrP143-153 (■) and three samples of ovine plasma spiked with 24 to 380 
pg/ml PrP143-153 (●)(▲)(▼).  (B) PrP143-153 was stable in ovine plasma at 37°C.  920 
pg/ml PrP143-153 was added to ovine plasma, and tubes were incubated at 37°C for 
different time points.  Each value represents the data from duplicates of the RIA. 
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Table 2. The concentration of PrPC fragments in ovine plasma sample = observed - 
analyte (PrP143-153).  Each value represents the data from duplicates of the RIA. 
Standard addition of ovine plasma sample 
 
 
2.5 Discussion 
  Our present findings showed that 125I-recPrP was not appropriate to be used 
as a tracer in RIA due to high non-specific binding and short life span.  In contrast, 
125I-PrP143-153 as a tracer and goat anti-PrP143-153 as first antibody performed well in 
the RIA.  The present study showed the RIA of PrP143-153 detected the concentration 
of PrPC fragments in brain homogenate and plasma samples from sheep.  In healthy 
sheep, the concentration of PrPC fragments was 0.29 μg/g total proteins in a brain 
homogenate, and 99 pg/ml in a plasma sample.  The sensitivity of the RIA was 31 
pg/ml, and both intra-assay and inter-assay variability was <10%.  In addition, <10% 
of PrP143-153 was degrade in plasma after 6 hr of incubation at 37°C. 
Is PrP143-153 specific for PrPC?  We did a search of the sequence 
SDYEDRYYREN in the NCBI protein database and RCSB protein data bank.  The 
results indicated that this sequence is only in PrPC, but not other known proteins.  
Thus, the concentration of the fragments only reflects the degradation of PrPC.  The 
data showed fragments containing PrP143-153 in ovine brain homogenate was 0.29 μg/g 
Analyte  (pg/ml)
Observed (pg/ml)
(Mean ± SE)
Observed mean - Analyte
24 148 ± 7.1 124
48 157 ± 7.8 109
95 208 ± 7.7 113
190 314 ± 13 124
380 499 ± 27 119
118Mean (Observed - Analyte)
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of total proteins.  If the amount of PrPC fragments is calculated to express that of 
intact PrPC (MW of PrP143-153: MW of PrPC = 1,500 : 35,000), it indicates that this 
amount of fragments would be released from 6.1 μg of intact PrPC.  A previous study 
showed that the concentration of PrPC in hamster brain homogenate was 70 μg/g total 
protein [19].  By taking these two numbers into consideration, we speculate that 
8.7% of PrPC would be constantly degraded and released from the plasma membrane 
of PrPC-containing cells, e.g., neurons. 
We hypothesize that the RIA of PrP143-153 is difficult to detect intact PrPC in the 
brain homogenate for three reasons:  First, the data showed that 6.1 μg PrPC was 
detected in an ovine brain homogenate, which is 10 times less than the result from a 
previous study.  Second, the brain homogenate digested by proteinase K showed 
more detectable fragments have been released.  Third, ovine recPrP was not detected 
by this RIA.  However, unlike PrPC, recPrP does not have the posttranslational 
modification.  Therefore, it is necessary to use pure PrPC to further verify the 
hypothesis that the RIA of PrP143-153 is difficult to detect intact PrPC.   
Can goat anti-PrP143-153 antibody recognize the peptide whose sequence is not 
fully identical to human PrP143-153?  Although the first amino acid of ovine PrP143-153 
is different from that of human PrP143-153, there was no difference between standard 
curves set by human PrP143-153 and ovine PrP143-153 (Figure 2B).  Also, the serial 
dilution of ovine brain homogenate showed parallelism with the standard curve of 
human PrP143-153.  These results suggested the difference of the first amino acid of 
N-terminal of the peptide does not affect the interaction between goat anti-PrP143-153 
antibody and PrPC fragments.  In addition, cervids have an identical PrP143-153 with 
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sheep.  Therefore, this RIA can be used to analyze the samples from cervids as well.  
For future studies, one should use the ovine peptide as standards to assay ovine/cervid 
plasma samples. 
Through epitope mapping by the 13-mer synthetic peptide, a previous study 
indicated that the epitope of 6H4 mAb recognizes 144-152 in human PrP [17].  
However, another study showed that 6H4 mAb did not bind the 25-mer synthetic 
peptide [18].  In addition, in the pair-wise epitope mapping, POM1 mAb competed 
with 6H4 mAb, which suggested the epitope of POM1 mAb corresponds to 6H4 
epitope.  Our results showed that neither 6H4 mAb nor POM1 mAb bound PrP143-153.  
In contrast, there was a binding between PrP143-153 and goat anti-PrP143-153 antibody.  
6H4 mAb was raised using bovine recPrP as the antigen in Prnp0/0 mice, and POM1 
mAb was raised using mouse recPrP in Prnp0/0 mice.  On the contrary, goat 
anti-PrP143-153 antibody was raised using synthetic peptide with the sequence of 
C-SDYEDRYYREN as an antigen.  The discrepancy of these antibodies might be 
caused by different physical structures of PrP143-153 between recPrP and the synthetic 
peptide.  Although 6H4 mAb and POM1 mAb have the major epitope on first 
α-helix of PrP, the interaction might be assisted by other amino acids or structures 
near this region. 
What is the relationship between the amount of PrPC and prion disease?  
In the diseased animals, a large amount of PrPC is converted to PrPSC and forms 
aggregates that are resistant to degradation.  Eventually, due to the depletion of PrPC, 
the production of PrPC fragments is expected to decrease.  Thus, we hypothesize that 
the amount of PrPC fragments (PrP143-153) in animals with prion disease is lower than 
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that of healthy animals.  Because no sufficient evidence supports that PrPC can be 
transported through the blood brain barrier, the PrPC in the blood most likely comes 
from peripheral nerve systems (PNS), platelets and follicular dendrite cells (FDCs) 
[20, 21].  At the early stage of a prion disease, PrPSC is replicated and accumulated 
on FDCs in secondary lymphoid tissues and then slowly invades PNS.  This process 
might decrease PrPC fragments in the blood.  This hypothesis needs to be tested 
through assaying the plasma samples from animals with and without prion disease.  
In conclusion, we developed the RIA of PrP143-153, and it could detect PrPC 
fragments in brain homogenate and plasma samples. Based on our hypothesis, this 
RIA has a potential to be used as a screening test for diagnosis of scrapie and CWD 
using plasma samples. 
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